Functions of exosomal microRNAs from adipose tissue in diabetes mellitus and related cardiovascular pathologies.
Li YZ., Zhang YT., Li XH.
Narrative Review on Type 2 Diabetes, published in Cell Cycle (2026) — summary generated from the PubMed abstract.
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Cell Cycle (2026)
- Country
- United States
- Reported sample size
- —
- PMID
- 41249941
- DOI
- 10.1080/15384101.2025.2590058
Abstract (original English)
Adipose tissue is central to energy homeostasis and endocrine function, and its dysregulation is a key driver of metabolic disorders. Exosomes, serving as critical intercellular messengers, mediate systemic metabolic responses by delivering bioactive cargo, including nucleic acids, proteins, and lipids. Mounting evidence identifies adipose-derived exosomes as potent mediators of obesity-related inflammation and glucose metabolic dysfunction, thereby contributing to insulin resistance and diabetic complications. This review summarizes the pivotal roles of exosomal microRNAs (miRNAs) and highlights their significant potential as a novel class of small RNA therapeutics. Unlike synthetic delivery systems, exosomal miRNAs constitute an inherent delivery vehicle that synergizes natural targeting efficiency with potent gene regulatory functions. This unique combination enables the precise coordination of complex gene networks involved in metabolic disease, offering a distinct advantage over conventional single-target approaches. Consequently, exosomal miRNAs are positioned as promising candidates for pioneering RNA-based therapies against pervasive conditions such as diabetes and cardiovascular disease.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
There is currently not enough data to draw conclusions about benefit or risk for this topic.
How we grade evidenceRelated research
- Level ASystematic Review
Systematic Review: Exosomes as Molecular Messengers in the Development of Obesity-Related Complications in Children.
Systematic Review on Type 2 Diabetes, published in Curr Issues Mol Biol (2025) — summary generated from the PubMed abstract.
- 2025
Curr Issues Mol Biol - Level AMeta-analysis
Type 2 Diabetes Mellitus Induced Paracrine Effects on Breast Cancer Metastasis Through Extracellular Vesicles Derived from Human Mesenchymal Stem Cells.
Meta-analysis on Type 2 Diabetes, published in Stem Cells Dev (2020) — summary generated from the PubMed abstract.
- 2020
Stem Cells Dev - Level ASystematic Review
Adipose-derived Mesenchymal Stem Cells in the Treatment of Obesity: A Systematic Review of Longitudinal Studies on Preclinical Evidence.
Systematic Review on Type 2 Diabetes, published in Curr Stem Cell Res Ther (2018) — summary generated from the PubMed abstract.
- 2018
Curr Stem Cell Res Ther - Level AMeta-analysis
Metabolic effects of large-volume liposuction for obese healthy women: a meta-analysis of fasting insulin levels.
Meta-analysis on Type 2 Diabetes, published in Aesthetic Plast Surg (2014) — summary generated from the PubMed abstract.
- 2014
Aesthetic Plast Surg - Level BClinical Trial
Safety and efficacy of autologous adipose tissue-derived stem cell transplantation in aging-related low-grade inflammation patients: a single-group, open-label, phase I clinical trial.
Clinical Trial on Type 2 Diabetes, Neuroinflammation, Immune Modulation, published in Trials (2024) — summary generated from the PubMed abstract.
- 2024
Trials - Level BRandomized Controlled Trial
Using adipose-derived mesenchymal stem cells to fight the metabolic complications of obesity: Where do we stand?
Randomized Controlled Trial on Type 2 Diabetes, Immune Modulation, published in Obes Rev (2022) — summary generated from the PubMed abstract.
- 2022
Obes Rev